ACE-031 research monograph — the soluble ActRIIB myostatin trap and its halted clinical record

ACE-031 (research generic name: ramatercept) is a soluble activin receptor type IIB–IgG1 Fc fusion protein — an "ActRIIB-Fc" decoy receptor. Although it is grouped with research peptides, it is technically a recombinant biologic (~110 kDa fusion protein), not a synthetic peptide. ChEMBL: CHEMBL2108674; highest clinical phase reached: 2.

Class

Myostatin/activin inhibitor — a soluble ActRIIB-IgG1 Fc fusion protein (decoy receptor). Single compound.

Mechanism

ACE-031 is the extracellular domain of the activin receptor type IIB (ActRIIB) fused to the Fc region of human IgG1. It works as a soluble decoy: it binds and sequesters ActRIIB ligands — myostatin (GDF-8), activin A, and GDF-11 — before they can reach the membrane-bound receptor. Because myostatin is a negative regulator of skeletal muscle, trapping it de-represses muscle growth, producing gains in muscle mass and strength. The same ligand family also influences bone turnover (research showed reduced resorption and increased bone-formation markers). Critically, ActRIIB ligands also help regulate the vasculature — and off-target inhibition of those ligands is the mechanistic basis for the program's defining safety problem.

Research summary

ACE-031 is unusually well-documented for a research compound, with real registered human-trial data rather than animal work alone:

• Preclinical / non-human primate: a 2025–26 study in the common marmoset (PLOS One; also bioRxiv/PubMed) confirmed increased muscle mass and strength in a non-human primate, extending earlier rodent (RAP-031 surrogate) findings.
• Phase 1 (NCT00755638, NCT00952887; healthy postmenopausal women; Attie et al. 2013, Muscle & Nerve): single and multiple ascending subcutaneous doses produced dose-dependent increases in lean/thigh muscle mass plus favorable bone-marker shifts. Even at this stage, notable adverse events included dilated blood vessels and nosebleeds.
• Phase 2 (NCT01099761; ambulatory steroid-treated boys with Duchenne muscular dystrophy; Campbell et al. 2017, Muscle & Nerve): escalating dose vs placebo, 12 weeks plus 12-week follow-up. The trial was stopped early and the open-label extension (NCT01239758) was terminated on preliminary safety grounds. Because of the early halt, efficacy was never established.

Studied protocols

In trials, ACE-031 was given by subcutaneous injection on an infrequent schedule (roughly every 2–4 weeks), enabled by the long half-life of the Fc-fusion format; the DMD program used escalating, weight-based dosing. These describe what was studied in registered trials — not a recommended protocol. There is no established research-use protocol outside the discontinued clinical program.

Stacking research

No published peptide-stacking research. In the DMD trials it was administered on top of background corticosteroids (standard of care), not as a designed combination. It is mechanistically adjacent to Acceleron's later ActRII drugs (luspatercept, sotatercept), but those are distinct molecules and were not co-administered with ACE-031.

Clinical / safety context

Development was discontinued (~2013) and ACE-031 was never approved for any indication. The defining finding of the whole program is a safety signal: off-target inhibition of vascular-regulating ligands caused telangiectasia (spider veins), epistaxis (nosebleeds), and gum bleeding. This is the single most important thing the research record establishes about the compound.

Evidence quality — Moderate (safety-weighted)

Far better documented than most research peptides (multiple registered human trials plus recent non-human-primate data), but the human studies were small, Phase 2 was halted, efficacy was never proven, and there is no long-term safety data. The strongest, most actionable conclusion the literature supports is the vascular safety risk — not a muscle-growth efficacy claim.

Notes

ACE-031 is a recombinant Fc-fusion protein, not a synthetic peptide — it behaves like a biologic (large, cell-culture produced, long half-life, subcutaneous dosing). "ActRIIB-Fc" and "ramatercept" refer to the same molecule; do not confuse it with luspatercept or sotatercept. Expect it supplied as a lyophilized research protein.